Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
A Window Study of Ixazomib in Untreated Indolent B-NHL
NCT02339922Phase 2Active, not recruiting
- Sponsor
- University of Washington
- Start
- May 2016
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ixazomib in chronic lymphocytic leukemia (CLL), follicular lymphoma (FL), Lymphoplasmacytic Lymphoma (LPL) and 4 more, sponsored by University of Washington. Primary endpoint: Overall Response Rate up to 5 years. Started May 2016; status: active, not recruiting.
02
Drugs
ixazomib
03
Conditions
chronic lymphocytic leukemia (CLL)follicular lymphoma (FL)Lymphoplasmacytic Lymphoma (LPL)mantle cell lymphoma (MCL)marginal zone lymphoma (MZL)
Beyond the preview
Go deeper on NCT02339922.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02339922.